Toluene

Toluene

SCHEMBL1079482

CC(=O)Cc1ccc(C)c(CC(C)=O)c1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1.Cc1ccccc1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 2/20 0.39
CTBP2 P56545 3/20 0.39
SLC22A12 Q96S37 2/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MAOB P27338 1/20 0.36
SRD5A2 P31213 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL8994440 1.00 L3MBTL1 (0.41) L3MBTL1TDP1SMN1; SMN2LMNAMEN1
Toluene SCHEMBL8907280 1.00 L3MBTL1 (0.41) L3MBTL1TDP1SMN1; SMN2LMNAMEN1
Toluene SCHEMBL1159746 1.00 L3MBTL1 (0.41) L3MBTL1TDP1SMN1; SMN2LMNAMEN1
SCHEMBL7789892 0.90 POLB (0.42) L3MBTL1TDP1LMNAMEN1KMT2A
SCHEMBL2332010 0.85 SLC22A12 (0.44) TDP1SMN1; SMN2LMNAMEN1KMT2A
Toluene SCHEMBL1245378 0.83 L3MBTL1 (0.45) L3MBTL1TDP1SMN1; SMN2LMNAMEN1
Toluene SCHEMBL7782221 0.83 L3MBTL1 (0.45) L3MBTL1TDP1SMN1; SMN2LMNAMEN1
Toluene SCHEMBL1245372 0.83 L3MBTL1 (0.45) L3MBTL1TDP1SMN1; SMN2LMNAMEN1
Toluene SCHEMBL1078154 0.83 L3MBTL1 (0.45) L3MBTL1TDP1SMN1; SMN2LMNAMEN1
SCHEMBL210161 0.81 PKM (0.42) L3MBTL1LMNAMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11311423-B2 Facial patch NICHIBAN CO., LTD. (JP) 2022-04-26 US disclosed
CN-104955426-B Patch containing clobetasol for treating eyelid diseases 千寿美国公司 2019-01-11 CN disclosed
EP-2937066-B1 FACIAL PATCH NICHIBAN KK (JP) 2018-04-25 EP disclosed
EP-2934403-B1 PATCH FOR TREATMENT OF EYELID DISEASES CONTAINING CLOBETASOL SENJU USA INC (US) 2018-03-21 EP disclosed
US-9211397-B2 Patch for treatment of eyelid disease containing clobetasol SENJU USA, INC. (US) 2015-12-15 US disclosed
US-20150320606-A1 Facial Patch NICHIBAN CO., LTD. (JP) 2015-11-12 US disclosed
EP-2937066-A1 FACIAL PATCH Nichiban Co. Ltd. (JP) 2015-10-28 EP disclosed
EP-2934403-A2 PATCH FOR TREATMENT OF EYELID DISEASES CONTAINING CLOBETASOL SENJU USA, INC. (US) 2015-10-28 EP disclosed
CN-104955426-A Patch containing clobetasol for treating eyelid diseases SENJU USA INC 2015-09-30 CN disclosed
WO-2014099894-A2 PATCH FOR TREATMENT OF EYELID DISEASES CONTAINING CLOBETASOL SENJU USA, INC. (US) 2014-06-26 WO disclosed
CN-1235908-C 16,17-carbocyclic condensed steroid compounds having seletive estrogenic activeity AKZO NOBEL NV (NL) 2006-01-11 CN disclosed
EP-1294739-B1 16,17-CARBOCYCLIC CONDENSED STEROID COMPOUNDS HAVING SELECTIVE ESTROGENIC ACTIVITY AKZO NOBEL NV (NL) 2005-04-13 EP disclosed
US-20040102426-A1 16,17-carbocyclic condensed steroid compounds having selective estrogenic activity MERCK SHARP & DOHME B.V. (NL) 2004-05-27 US disclosed
CN-1433426-A 16,17-carbocyclic condensed steroid compounds having seletive estrogenic activeity AKZO NOBEL NV (NL) 2003-07-30 CN disclosed
EP-1294739-A1 16,17-CARBOCYCLIC CONDENSED STEROID COMPOUNDS HAVING SELECTIVE ESTROGENIC ACTIVITY Akzo Nobel N.V. (NL) 2003-03-26 EP disclosed
WO-2002000682-A1 16, 17-CARBOCYCLIC CONDENSED STEROID COMPOUNDS HAVING SELECTIVE ESTROGENIC ACTIVITY AKZO NOBEL N.V. (NL) 2002-01-03 WO disclosed
US-6017556-A PROTECTING HUMAN HAIR FROM THE DAMAGING EFFECT OF ULTRAVIOLET RADIATION BY TREATING HUMAN HAIR WITH A LIPOSOMOGENIC ULTRAVIOLET RADIATION ABSORBER CIBA SPECIALTY CHEMICALS CORPORATION (US) 2000-01-25 US disclosed
US-5352684-A Antitumor, anticarcinogenic agents BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1994-10-04 US disclosed
US-4965283-A Anticonvillsants, antiepileptic agents DR. WILLMAR SCHWABE GMBH & CO. (DE) 1990-10-23 US disclosed
US-4943568-A Cephalosporins BAYER AKTIENGESELLSCHAFT (DE) 1990-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102426-A1 16,17-carbocyclic condensed steroid compounds having selective estrogenic activity ESR2, HSD17B11, ESRRA L3MBTL1 2767/4885TDP1 4595/4885SMN1; SMN2 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.